MicroRNA biosensors for detection of Alzheimer’s disease

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-05-31 DOI:10.1016/j.cca.2025.120410

Asma Vafadar , Mohammad Younesi , Mohammad Ehsan Maddahi , Sajad Ehtiati , Hossein Moradi Kazerouni , Faranak moradi khalaj , Hasan Ghasemi , Amir Savardashtaki

引用次数: 0

Abstract

Alzheimer’s disease (AD) is a critical global health problem characterized by cognitive degeneration and memory loss. Recent advancements in MicroRNA (miRNA) research have revealed their crucial role in AD development, Leading the way for early diagnosis and targeted treatments. Nanomaterials, renowned for their exceptional properties, have been integrated into biosensors to create highly sensitive and specific diagnostic tools. Among these, electrochemical biosensors, known for their simplicity and affordability, are particularly promising for clinical applications and point-of-care diagnostics. This review focuses on the application of miR-based electrochemical biosensors in early AD detection. We explore the innovative use of nanoparticles to enhance the sensitivity and specificity of these biosensors.

查看原文本刊更多论文

用于阿尔茨海默病检测的MicroRNA生物传感器

阿尔茨海默病（AD）是一种严重的全球性健康问题，其特征是认知退化和记忆丧失。最近对MicroRNA （miRNA）研究的进展揭示了它们在AD发展中的关键作用，为早期诊断和靶向治疗提供了途径。纳米材料以其独特的特性而闻名，已被集成到生物传感器中，以创造高灵敏度和特异性的诊断工具。其中，电化学生物传感器以其简单和可负担性而闻名，在临床应用和即时诊断方面尤其有前景。本文综述了基于mir的电化学生物传感器在AD早期检测中的应用。我们探索纳米颗粒的创新使用，以提高这些生物传感器的灵敏度和特异性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.